Mind the Brain

MTB optimally mitigates the dementia pandemic currently plaguing us and forecast to devastate at least 20% of every generation's population within two decades by protecting early childhood development brains from concussive events and traumatic brain injury by leveraging proteomic biomarkers to deliver best interventional brain protection practices, products, and biotherapeutics.  Everyone cares about our work because, without it, a significant part of our population's brains won't function such that they may care in the first place.

MTB provides earliest alerts and longitudinal confirmations of concussive event indications (such as traumatic brain injuries, chronic  traumatic encephalopathies, and the like) via specific large-molecule proteins observed to cross the blood-brain barrier.  MRI's used today take too long, cost too much, and don't scale - limits of the current practice - our blood-based tests solve this triple threat.

MTB optimally mitigates the dementia pandemic currently plaguing us and forecast to devastate at least 20% of every generation's population within two decades by protecting early childhood development brains from concussive events and traumatic brain injury by leveraging proteomic biomarkers to deliver best interventional brain protection practices, products, and biotherapeutics.

We serve the global early childhood population.

Latest research shows that compromised blood-brain barriers caused by early childhood concussive events are most prevalent in dementia patients and what is new in our approach is the generational-timeframe longitudinal studies on the order of approximately 15 to 20 years required to confirm and refine these findings and resulting interventional products and biotherapeutics.

Risks in the life sciences are well-known, including long-lead approvals from the FDA, insufficient capabilities analysis techniques and equipment, and the real possibility that attribution to certain proteins may not be possible given current technologies.  But initial work and results are promising, so we proceed with humility and hope in the face of this pandemic.

We are disabused of the notion that we will completely solve this tough tech problem in our lifetimes (though we strive for breakthrough results and immediately applicable technologies that may be commercialized as we progress) and believe that The Engine is the best home to nurture MTB.

Our founder draws upon his MIT Course II undergraduate work and subsequent industry experience to lead the team relying on seminal work from Orlando Health, Banyan Biomarkers, and the Brain Institute faculty at The University of Florida.  Proposed MIT and New England network includes Dr. Laurence Young's and colleagues' work in Course XVI and centers, Simbex's Rick Greenwald for his decades of best-in-class theoretical and empirical work in the field including commercialization, and KCAS Bioanalytical & Biomarker Services, among others.

We consider every patient exam to be one of our "mid-terms" and, taken collectively as a measure of patient health, consider their optimal cognitive functioning as well as the health of MTB to be our final exam.

We look forward to Solve assisting Mind The Brain.  Thank you for your consideration.

Our work is new and everyone cares about our work because, without it, a significant part of our population's brains won't function such that they may care in the first place.

MTB provides earliest alerts and longitudinal confirmations of concussive event indications (such as traumatic brain injuries, chronic  traumatic encephalopathies, and the like) via specific large-molecule proteins observed to cross the blood-brain barrier.  MRI's used today take too long, cost too much, and don't scale - limits of the current practice - our blood-based tests solve this triple threat.

Our linking and preventing the earliest blood-brain barrier compromises to prevent dementia is what's new here.  The current practice is retrospective study of cause with scant significant prevention modalities or products.

Our linking and preventing the earliest blood-brain barrier compromises in early childhood development to prevent dementia longitudinally is what's new here.  The current practice is retrospective study of cause with scant significant prevention modalities or products.

Currently:  test cohorts up to approximately 100

One Year:  test cohorts up to approximately 1,000

Five Years:  patient cohorts up to approximately 1,000,000

Scale into society at critical early childhood development stages to safeguard brains from concussive events to prevent dementia longitudinally.

Generational-timeframe longitudinal studies on the order of approximately 15 to 20 years required to confirm and refine these findings and resulting interventional products and biotherapeutics.

Development of best-practice design-of-experiment methods to accelerate valid longitudinal testing.

FTE:  2

PT/Contractors:  3

Our founder draws upon his MIT Course II undergraduate work and subsequent industry experience to lead the team relying on seminal work from Orlando Health, Banyan Biomarkers, and the Brain Institute faculty at The University of Florida.  Proposed MIT and New England network includes Dr. Laurence Young's and colleagues' work in Course XVI and centers, Simbex's Rick Greenwald for his decades of best-in-class theoretical and empirical work in the field including commercialization, and KCAS Bioanalytical & Biomarker Services, among others.

Our founder draws upon his MIT Course II undergraduate work and subsequent industry experience to lead the team relying on seminal work from Orlando Health, Banyan Biomarkers, and the Brain Institute faculty at The University of Florida.  Proposed MIT and New England network includes Dr. Laurence Young's and colleagues' work in Course XVI and centers, Simbex's Rick Greenwald for his decades of best-in-class theoretical and empirical work in the field including commercialization, and KCAS Bioanalytical & Biomarker Services, among others.

For-profit b2b for initial roll-out support b2c as tests and biopharmaceuticals are commercialized.

DOD and Darpa SBIR funding and incubating at MIT's Engine for Tough Tech Founders provide foundational stability through scaling stages.  Self-supporting sales continue the trajectory to profitability.

Given President Reif's charge to Alumni to build a better world (ref http://www.mit.edu/building-a-...), we step up.

Proposed MIT and New England network includes Dr. Laurence Young's and colleagues' work in Course XVI and centers, Simbex's Rick Greenwald for his decades of best-in-class theoretical and empirical work in the field including commercialization, and KCAS Bioanalytical & Biomarker Services, among others.